Innate Pharma S.A.
IPHA | NASDAQ
$1.82
-$0.04 (-2.15%)
Sep 22, 2026, 1:47 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q4 2025 Dec 30, 2025 | Q2 2025 Jun 29, 2025 | Q4 2024 Dec 30, 2024 | Q2 2024 Jun 29, 2024 | Q4 2023 Dec 30, 2023 | Q2 2023 Jun 29, 2023 | Q4 2022 Dec 30, 2022 | Q2 2022 Jun 29, 2022 | Q4 2021 Dec 30, 2021 | Q2 2021 Jun 29, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.08M | 2.79M | 5.14M | 12.62M | 28.9M | 51.9M | 43.65M | 49.58M | 44.06M | 12.11M | 36.31M |
Cost of Revenue | n/a | 20.52M | -8.56M | n/a | 53.65M | 40.3M | 29.08M | 25.83M | 25.38M | 23.5M | 15.26M |
Gross Profit | 18.45M | 2.79M | 13.69M | 12.62M | -19.86M | 16.49M | 14.57M | 23.75M | 18.69M | -11.39M | 21.06M |
Operating Income | -49.85M | -53.43M | -50.69M | -51.58M | -33.73M | -12.67M | -34.06M | -24.63M | -26.73M | -57.48M | -43.99M |
Interest Income | 7.39M | 7.67M | 665K | 2.64M | 14.48M | 12.9M | 1.31M | 350K | 4K | 7.5K | 32K |
Pretax Income | -50.3M | -49.18M | -46.05M | -49.47M | -29.2M | -7.57M | -71.25M | -66.01M | -27.31M | -58.07M | -89.19M |
Net Income | -47.51M | -48.97M | -46.05M | -49.47M | -34.05M | -7.57M | -62.69M | -58.1M | -22.79M | -52.81M | -77.37M |
Selling & General & Admin | 8.7M | 11M | 12.12M | 11.93M | 18.73M | 17.69M | 18.11M | 20.94M | 16.88M | 18.89M | 29.44M |
Research & Development | 22.93M | 43.45M | 43.42M | 51.98M | 53.65M | 52.98M | 53.57M | 48.85M | 49.49M | 46.13M | 42.11M |
Other Expenses | 39.2M | 1.76M | 8.84M | 283K | -53.64M | -24.57M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 70.83M | 56.21M | 64.38M | 64.2M | 18.73M | 46.1M | 71.68M | 69.79M | 66.37M | 65.02M | 71.55M |
Interest Expense | 3.04M | 2.87M | 34K | 634K | 3.62M | 3.35M | 418K | 94K | n/a | n/a | n/a |
Selling & Marketing Expenses | -156K | n/a | -8K | n/a | 338K | 245K | 148.5K | 265K | 326.5K | 196.5K | 222K |
Cost & Expenses | 50.93M | 56.21M | 55.83M | 64.2M | 62.63M | 64.57M | 77.71M | 74.21M | 70.79M | 69.59M | 80.3M |
Income Tax Expense | -5.58M | -2.99M | n/a | n/a | n/a | -4.85M | -8.62M | -8.04M | -11.93M | -12.59M | -11.82M |
Shares Outstanding (Basic) | 93.83M | 91.41M | 85.38M | 81.05M | 79.88M | 80.59M | 80.32M | 80.19M | 79.74M | 79.54M | 79M |
Shares Outstanding (Diluted) | 93.83M | 91.41M | 86.94M | 81.05M | 80.87M | 80.59M | 83.78M | 80.19M | 81.87M | 79.54M | 79M |
EPS (Basic) | -0.51 | -0.55 | -0.55 | -0.61 | -0.43 | -0.10 | -0.78 | -0.72 | -0.29 | -0.67 | -0.98 |
EPS (Diluted) | -0.51 | -0.55 | -0.55 | -0.61 | -0.43 | -0.10 | -0.78 | -0.72 | -0.29 | -0.67 | -0.98 |
EBITDA | -52.55M | -55.77M | -46.41M | -46.91M | -35.96M | -9.56M | -9.25M | -3.86M | -20.69M | -53.19M | -80.09M |
EBIT | -53.23M | -56.8M | -48.02M | -48.91M | -38.58M | -15.08M | -15.27M | -8.21M | -25.04M | -57.76M | -88.84M |
Depreciation & Amortization | 1.29M | 1.04M | 1.61M | 1.99M | 2.62M | 5.52M | 6.03M | 4.42M | 4.42M | 4.57M | 8.76M |
Add to Watchlist
Select watchlists to add or remove IPHA